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During the past decade, rotavirus genotype G9 has
spread throughout the world, adding to and sometimes
supplanting the common genotypes G1–G4. We report evi-
dence of this spread in a population sample within rural
Ecuador. A total of 1,656 stool samples were collected from
both patients with diarrhea and from asymptomatic resi-
dents in 22 remote communities in northwestern Ecuador
from August 2003 through February 2006. Rotavirus was
detected in 23.4% of case-patients and 3.2% of controls.
From these 136 rotavirus-positive samples, a subset of 47
were genotyped; 72% were of genotype G9, and 62% were
genotype P[8]G9. As a comparison, 29 rotavirus-positive
stool samples were collected from a hospital in Quito dur-
ing March 2006 and genotyped; 86% were of genotype
P[8]G9. Few countries have reported P[8]G9 rotavirus
detection rates as high as those of the current study. This
growing prevalence may require changes to current vacci-
nation programs to include coverage for this genotype.
R
otavirus is the most important cause of acute gastroen-
teritis and death in infants and young children world-
wide, causing an estimated 352,000–592,000 deaths in
children <5 years of age (1). Although the incidence of
infection in children in industrialized and developing
countries is similar, outcomes vary widely. In countries
classified by the World Bank as high-income, the risk of
dying from rotavirus before age 5 is 1 in 48,680; the equiv-
alent risk in low-income countries is 1 in 205 (1).
The rotavirus genome is made up of 11 double-strand-
ed RNA segments; each segment encodes a unique struc-
tural or nonstructural protein. A 3-layered protein coat
encloses the genetic material. The VP2 proteins form the
innermost layer, which is in turn surrounded by a sheet of
VP6 proteins. The outer layer consists of 2 antigenic pro-
teins, VP7 and VP4, also referred to as the G (glycopro-
tein) and P(protease-sensitive) proteins, respectively (2,3).
To date, 15 G-protein genotypes and 24 P-protein geno-
types have been identified (3), of which 10 G and 12 P
types are known to infect humans. The combination of
these 2 proteins constitutes the viral genotype (4). Because
of the segmented nature of the rotavirus genome, the genes
for the external structural proteins may segregate inde-
pendently during coinfection (genetic reassortment), thus
increasing the genetic diversity of rotaviruses.
Data from 1994 through 2003 indicate that the 4 most
prevalent human rotavirus genotypes worldwide were
P[8]G1 (52%), P[4]G2 (11%), P[8]G4 (8%), and P[8]G3
(3%), which together represented ≈74% of the global iso-
lates (2). In Latin America during the same period, the
prevalence of these 4 viral types was similar (3,5).
More recent data suggest that the G9 genotype has
gained global importance during the past 10 years (3,6–9).
The P[8]G9 type, the most common combination, may
have resulted from a reassortment event between the most
prevalent type P[8] and a strain carrying G9. From 1990
through 2004, P[8]G9 rotaviruses caused <5% of
rotavirus infections worldwide but 15% of infections in
South America (2,3). A less common reassortment is
P[6]G9 (2,6).
Genotyping of circulating strains has epidemiologic
importance and relevance for vaccination planning. The
most efficacious vaccination protocols are those that use
viral serotypes similar to those circulating in a given com-
munity (homotypic responses) (3). Vaccines with
serotypes distinct from those circulating (heterotypic) are
less effective (9,10).
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Ecuador (11), to our knowledge, this is the first report of
circulating genotypes. The data presented here are unique
in that they are community-based and include all sympto-
matic community residents as well as asymptomatic con-
trols. This approach differs from most rotavirus
genotyping studies, which focus on patients in a clinical
setting. The data thus document the total illness rate asso-
ciated with rotavirus infection from 22 remote, rural com-
munities on the northern coast of Ecuador.
Methods
Study Population and Design
As part of a larger community-based case-control
study, fecal samples were collected from persons in 22
remote communities located in Esmeraldas, the northern-
most province on the coast of Ecuador. Each of 21 small,
rural communities was visited 4 times, each time for 15
days, from August 2003 through February 2006. Fecal
samples were also collected from the region’s largest town,
Borbón, for 15 days in July 2005. During each 15-day
visit, health workers visited every household and inter-
viewed residents to identify every case of diarrhea. For
each identified case of diarrhea, 3 asymptomatic controls
were selected, 1 from the case-patient’s household and 2
randomly selected from the community. A total of 1,656
stools samples were collected, 411 (25%) from patients
with diarrhea. 
To determine whether the results in these remote com-
munities were representative of rotavirus infections in
other Ecuadorian locations, 29 fecal samples from children
<5 years of age with rotavirus-associated diarrhea
rotavirus were collected at the Hospital de Niños Baca
Ortiz in Quito, which is an urban environment ≈200 km
from the study area. Protocols were approved by the
bioethics committee at the Universidad San Francisco de
Quito and the Internal Review Board at the University of
California, Berkeley, California, USA.
Rotavirus Detection and Testing
All of the 1,656 samples (symptomatic and nonsymp-
tomatic) were analyzed for the presence of rotavirus with a
commercial immunochromatographic test (RIDA Quick
Rotavirus, R-Biopharm AG, Darmstadt, Germany). All
rotavirus-positive samples collected from February 2005
through February 2006 (n = 47) were preserved in liquid
nitrogen and transported to Quito for PCR genotyping. The
double-stranded rotavirus RNA was extracted from the
stool specimens by using TRIZOL Reagent (Invitrogen
Corp., Carlsbad, CA, USA) or the UltraClean Tissue RNA
Kit (MoBio Laboratories, Inc., Carlsbad, CA, USA)
according to manufacturer’s instructions. RNA was stored
at –80°C until further use. A 2-step, seminested multiplex
reverse transcription–PCR was carried out for G- and P-
genotyping based on a protocol provided by the US
Centers for Disease Control and Prevention (J. Gentsch,
pers. comm.). Briefly, primers 9con1 and 9con2 were used
for the first amplification of the VP7 gene and primers 9T-
1, 9T-2, 9T-3P, 9T-4, and 9T-9B were then used to ascer-
tain the G genotype (12). Primers Con3 and Con2 were
used for the partial amplification of the VP4 gene and
primers 1T-1, 2T-1, 3T-1, 4T-1, 5T-1, and ND2 were then
used to ascertain the P genotype (13).
Viral RNA was denatured for 5 min at 97°C.
Retrotranscription and the first amplification were carried
out by using a SuperScript III RT/Platinum Taq poly-
merase kit (Invitrogen Corp.). Primers were used at 200
nmol/L each, and the 1× buffer provided by the manufac-
turer contained 1.6 mmol/L MgSO4 and 200 µmol/L of
each deoxynucleotide triphosphate. The retrotranscription
was carried out at 42°C for 45 min and stopped at 96°C for
2 min. The first amplification consisted of 30 cycles at
94°C for 30 s, 50°C for 30 s, and 72°C for 60 s. The sec-
ond amplification was carried out by using PuReTaq
Ready-To-Go PCR beads (Amersham Biosciences,
Piscataway, NJ, USA) and primers at a final concentration
of 400 nmol/L. The cycling parameters were 30 cycles at
94°C for 30 s, 42°C for 30 s and 72°C for 60 s, and a final
extension at 72°C for 1 min. Electrophoresis of the PCR
product was conducted on 1.8% agarose gels at 60 volts
and visualized under ultraviolet light.
Nucleotide Sequencing
For sequencing purposes, samples were transferred
directly onto chromatography paper strips treated with
sodium dodecyl sulfate–EDTA, dried overnight at room
temperature, and sent to Belgium by standard postal serv-
ice (14). From the community samples, 22 PCR products
that were identified as P[8]G9 were purified with the
QIAquick PCR purification kit (QIAGEN, Hilden,
Germany), and sequenced with the ABI PRISM BigDye
Terminator Cycle sequencing reaction kit (Applied
Biosystems, Foster City, CA, USA) on an ABI PRISM
3100 automated sequencer (Applied Biosystems). Primers
Beg9 and End9 were used for the VP7 gene (15) and
primers 1-17F (16) and Con2 were used for the VP4 gene.
The sequencing reaction conditions were 25 cycles at 94°C
for 15 s, 50°C for 15 s, and 72°C for 4 min, and a final
extension of 72°C for 7 min.
Sequence Analysis
Partial VP7 DNA sequences from 22 G9 community
samples and 65 additional G9 VP7 sequences obtained
from GenBank for comparison purposes were aligned by
using ClustalW (17). A phylogenetic tree was constructed
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by DNAML in PHYLIP (18). A VP7 sequence from a G3
genotype rotavirus was used to root the tree. Bootstrap
support was calculated by using 500 bootstrapped data
replicates as implemented by SEQBOOT in PHYLIP. VP7
gene sequences from the 22 G9 community isolates were
deposited in GenBank under accession nos. DQ848566–
DQ848587.
Results
Of 1,656 fecal samples from remote communities ana-
lyzed for rotavirus, 136 (8.2%) were determined to be pos-
itive by the commercial immunochromatographic test. Of
these positive samples, 96 were from the 411 patients with
diarrhea and 40 were from the 1,245 asymptomatic con-
trols. Diarrhea was significantly associated with being
infected with rotavirus (odds ratio = 9.2; 95% confidence
interval 6.1–13.9). Rotavirus RNA was detected at the
highest rates from symptomatic infants and, surprisingly,
persons >40 years of age (Table 1). No pronounced sea-
sonality of rotavirus infection was determined, and inci-
dence was not significantly associated with month of
collection or with the observed 30-day rainfall for 15 days
before the visit and during the visit (data not shown). This
lack of seasonality in the tropics has been reported previ-
ously (19).
From the 136 rotavirus-positive community samples,
a subset of 47 samples were genotyped for the VP4 and
VP7 genes. This subset represented all samples collected
from February 2005 through February 2006, from 14 rural
communities and Borbón. Of these 47 samples, 35 (74%)
yielded successful PCR typing results for the VP4 gene
and 37 (79%) yielded successful PCR typing results for the
VP7 gene. An additional 6 (13%) yielded successful PCR
amplification at 1 of the 2 genes. The remaining 8 (17%)
samples were not typeable. Six of these untypeable RNA
samples, along with 6 typeable samples, were subjected to
electrophoresis on an agarose gel and visualized by stain-
ing with ethidium bromide in an attempt to detect rotavirus
RNA. None of the untypeable samples produced rotavirus
RNA banding patterns, whereas 3 of 6 typeable samples
could be visualized.
Among the successfully typed samples, genotypes
P[8] and G9 predominated. Asmall proportion of the sam-
ples produced patterns corresponding to P[6]G1 and
P[6]G9 (Table 2). Table 3 summarizes the percentage of
patients infected with P[8], G9, and P[8]G9 based on 2
assumptions of the 13 samples in which 1 or both of the
VP4 and VP7 genes were not typeable. The first assump-
tion was that samples were nontypeable because they were
degraded sometime between testing positive by
immunochromatographic tests in the field and the sample’s
arrival in the laboratory in Quito. In this case, we assumed
that those samples were missing data. The second assump-
tion was that the samples were nontypeable because they
were novel strains, and we therefore included them in the
dataset. G9 genotype was identified in 34 samples, result-
ing in a 72%–92% infection rate; P[8] genotype was iden-
tified in 31 samples, a 66%–89% infection rate; and the
combination of P[8]G9 was found in 29 samples, a
62%–88% infection rate.
To determine whether the genotypes in remote com-
munities corresponded to strains circulating elsewhere in
Ecuador, we analyzed 29 rotavirus-positive samples from
Hospital de Niños Baca Ortiz in Quito. Again, genotypes
P[8] and G9 overwhelmingly predominated (Table 2).
Electrophoretic evidence for 5 mixed infections was found
among these urban samples, but this was not seen among
the rural samples (Table 2).
Of the 29 P[8]G9 community samples, 22 were sent
for sequencing to the University of Leuven in Belgium.
Approximately 750 bp of high-quality nucleotide sequence
data for the VP7 gene was obtained from each sample. The
22 P[8]G9 samples were remarkably homogenous at the
sequence level, with only 3 single nucleotide polymor-
phisms found in the 22 sequences. Phylogenetic analysis
of the sequences (Figure) showed that the Ecuadorian
sequences grouped together monophyletically and were
part of the large clade composed of most of the recently
isolated G9 rotavirus sequences worldwide.
Discussion
The present study reports a high rate of infection
(72%–96%) with rotavirus G9 genotype among persons in
2 geographically distinct regions within Ecuador, a remote
coastal rain forest and an urban Andean hospital. To our
knowledge, it is the first description of rotavirus genotypes
in Ecuador, and the results support the observation that the
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Latin America. Also, the present study appears to be one of
the few community-based descriptions of rotavirus infec-
tion (20–22). Symptomatic persons were actively identi-
fied in the community, recruited into the study, and
matched with 3 asymptomatic controls each. This
approach presents a more complete picture of rotavirus
infection in rural communities than would be possible with
the clinical sampling used in most previous studies that
presumably focused on more urban environments. The
high rate of rotavirus infection among symptomatic per-
sons >40 years of age may be due to this age group’s lack
of exposure to the emerging rotavirus genotype and is an
observation that might have been missed in a purely clini-
cal study.
The G9 genotype has been documented since the early
1980s (23,24). Throughout much of the 1980s and 1990s,
G9 was considered very rare; however, recent reports have
described it as increasingly important (2,3,25). In the
United States, the G9 genotype was detected in a
1995–1996 outbreak (8) and maintained its presence in the
subsequent 2 years, with an average detection rate across
10 US cities of 7% (26). In Australia, the overall G9 detec-
tion rate, averaged across 3 population centers, increased
from <1% in 1997 to 29% in 2001 (27). In Japan, G9 was
essentially undetected throughout the mid-1980s and
1990s until it suddenly appeared in several cities in
1998–1999 (28). In India, G9 strains were detected for the
first time in the late 1980s and throughout the early 1990s
were usually found in combination with the P[11] or P[6]
genotypes at a detection rate of about 20% (12). Astudy of
6 population centers across India during 1996–1998 found
an overall G9 detection rate of 17% but found G9 as the
major strain (and for the first time associated mainly with
P[8] genotype) in New Delhi in late 1998 (29). At 17 sites
throughout the African continent during 1996–1999, the
G9 detection rate was generally <5% (30), with the excep-
tion of Ghana (1997–1999), where it comprised 28% of
rotavirus positive samples, and Nigeria (1998–1999),
where it comprised 37% (31). In Europe, many instances
of G9 detection have been reported from the late 1990s
through the early 2000s (16,32–34). 
Latin America, in particular, has seen a surge in dom-
inance of this genotype in recent years. In Rio de Janeiro,
Brazil, during 1997–1999, the detection rate was ≈15%
(6,7). In São Paulo, Brazil, during 1996–2003, the rate was
17% overall but in the last 2 years, G9 accounted for
30%–50% of rotavirus infections (35). To our knowledge,
only 4 studies have reported G9 detection rates as high as
those in our study: 75% in Paraguay, 2000 (36); 75%–90%
in Salvador, Brazil, 1999–2002 (9); 92% in Chiang Mai,
Thailand, 2000–2001 (37); and 73% in Alice Springs,
Australia, 2001 (27).
Apotential source of bias in this study comes from the
incomplete typing of 13% of the putatively rotavirus-posi-
tive specimens and the inability to type an additional 17%.
These incomplete or untypeable samples, which were pos-
itive by immunochromatographic tests, may be the result
of inappropriate handling or storage of some fecal sam-
ples, which can be complicated in remote community stud-
ies such as this. Typing failure because of sample
degradation or false-positive ELISA results is not likely to
result in biased results, and the lack of visualizable
rotavirus RNA bands among the untypeable samples sug-
gests that degradation is a likely cause of typing failure.
However, in any PCR-based typing scheme, typing failure
may be caused by primer–template mismatch, which could
bias results, especially with novel strains (16,38). A non-
systematic review of 16 recent studies suggests that failure
of PCR-based G-typing is relatively widespread, although
the failure rate varies. Four studies report <5% typing fail-
ure (16,33,35,37), 3 report 5%–10% failure (9,12,26), 2
report 10%–20% failure (29,36), 2 report 20%–30% fail-
ure (27,30), and 2 report >30% failure (31,34). An addi-
tional 3 studies do not explicitly state whether all typed
samples yielded results (6,7,32). A more complete picture
of global rotavirus diversity should facilitate efforts to
improve molecular typing techniques. In this study, the
maximum possible bias would affect the Esmeraldas com-
munity results by lowering the G9 infection rate from 92%
to 72% and the P[8]G9 from 88% to 62%. In the Quito
samples the effect is much less pronounced, potentially
lowering the G9 infection rate from 96% to 90% and
P[8]G9 rate from 93% to 86%. Further studies are required
to narrow this uncertainty; however, even the lower end
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Ecuador.
Additional evidence that G9 rotavirus is spreading
through Latin America comes from comparing our
nucleotide sequences to other sequences reported in
GenBank. The sequences from the current study cluster
into a large clade, which includes most of the recently iso-
lated G9 rotavirus reported in the literature. This “emerg-
ing clade” is relatively homogenous: most isolates within
the clade have <1% sequence divergence, an observation
about G9 that has been made previously (39). However,
the more recent regional isolates do tend to cluster togeth-
er, as is the case for subclades composed of strains from
Australia, Paraguay, or Ecuador (Figure). The low boot-
strap support for these subclades is due to the small num-
ber of single nucleotide polymorphisms differentiating
them.
The increasing prevalence of G9 rotavirus is particu-
larly relevant given that many countries, including
Ecuador, have approved the use of 2 rotavirus vaccines
(10,40), but despite the wide distribution of G9 during the
past 9 years (2,3,6–9), neither vaccine formulation
includes the serotype G9 antigen (10,40). Studies have
shown that some vaccines that do not contain the G9 anti-
gen may still be capable of eliciting protective immunity
against the G9 serotype (10). This immunity is most likely
attributable to the G9 genotype’s common association with
P[8], which is included in both vaccines. However, cross-
immunity may not be universal, as has been seen with type
P[4]G2 (2,3,10). Continual surveillance of circulating
types, therefore, should be carried out before to the intro-
duction and during the implementation of rotavirus vacci-
nation programs.
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